Browsing by Author "Ozer E.A."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cord blood nucleated red blood cell level: Is it a predictive marker for neonatal jaundice?
    (Walter de Gruyter GmbH, 2018) Orhon A.; Topal H.; Hakan N.; Ozer E.A.
    The aim of this study was to evaluate if the cord blood nucleated red blood cell (nRBC) levels can predict the development of hyperbilirubinemia in healthy neonates. All healthy newborn infants born after 35 or more weeks of gestation at our hospital between January 2016 and April 2017 were included. The levels of nRBC were counted in umbilical cord blood samples. Neonates were grouped into two study groups based on the presence or absence of neonatal jaundice. The study included overall 149 eligible newborn infants. The levels of nRBC and absolute nRBC count showed statistically significant differences between newborns with or without jaundice (p=0.01 and 0.02, respectively). We suggest that increased nRBC counts in cord blood may be a predictive marker for hyperbilirubinemia in healthy newborn infants. © 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants
    (Adis, 2018) Ilhan O.; Bor M.; Ozdemir S.A.; Akbay S.; Ozer E.A.
    Background: Given the severity and high mortality of multidrug-resistant Gram-negative bacilli (MDR-GNB) infections, the use of colistin will increase in patients with MDR-GNB infection. Objective: This study aims to assess the efficacy and safety of intravenous colistin in very low birth weight (VLBW; birth weight < 1500 g) preterm infants. Methods: We retrospectively analyzed the medical records of patients who received colistin between June 2016 and December 2017. The patients were assigned to two groups: the VLBW group and the non-VLBW group. Both groups were evaluated for response to treatment and adverse effects. Results: In total, 66 infants who received colistin therapy were included; of these, 28 infants were VLBW. All of our patients received standard colistin treatment of 5 mg/kg per day in three doses and the median duration of colistin treatment was 14 days. No significant differences were observed between the groups with respect to the efficacy of colistin (defined as showing microbiological clearance in control cultures and the absence of mortality during treatment) (89.3 vs 86.8%, p > 0.99). Serum magnesium and potassium levels were significantly lower in the VLBW group than in the non-VLBW group during colistin therapy (magnesium, 1.30 vs 1.70 mg/dL, p < 0.001; potassium, 3.6 vs 4.6 mEq/L, p < 0.001). Acute kidney injury was observed in four infants in the VLBW group and one in the non-VLBW group, without significant differences (p = 0.15). Conclusions: Colistin administration appears to be efficacious in VLBW infants; however, renal function tests and serum electrolytes should be monitored more closely in these infants during treatment. © 2018, Springer Nature Switzerland AG.